Search for:
Search for:
Healthcare Professionals
Publications
Contact
News
Español
Magazine
Radio
*
Get Educated
What is MS?
A chronic neurological disorder that affects the central nervous system, comprised of the brain...
More Details
Educational Materials
Common Questions
Lending Library
Symptoms
Treatment Options
Additional Resources
Research
MS Awareness Month
Donate
Get Help
Health & Wellness Program
Get educational materials and referrals, as well as the opportunity to participate in various...
Learn More
Grants & Programs
Awareness Campaigns
Support Groups
Events
Lending Library
Additional Resources
Get Involved
MS Awareness Month
An annual, nationwide campaign with goals to promote an understanding of MS, and to assist those...
Learn More
Advocacy
Buy from Partners
Volunteer
Businesses
MS Research Trials
Supporter Program
Awareness Campaigns
Host an Event
Events
MS Focus on Fashion
The inaugural MS Focus on Fashion, will take place on Nov. 6, in Dania Beach, Fla.
Learn More
Events Calendar
Health & Wellness
Fundraisers
Support
Web & Teleconferences
MS Education
Host an Event
About Us
Programs & Grants
More Details
Overview
Press Room
Leadership
Healthcare Advisory Board
Financial Statements
Our Mission
Careers at MS Focus
Affiliations
Assistive Technology P...
The Assistive Technology Program provides information about, and funding for, devices that help...
/Get-Help/MSF-Programs-Grants/Assistive-Technology-Program
Shop
Privacy
Terms of Use
Site Map
FDA approves new MS injection treatment
January 11, 2023
The FDA approved TG Therapeutics’ Briumvi (ublituximab-xiiy) injection treatment for patients with clinically isolated syndrome, relapsing-remitting, and active secondary progressive multiple sclerosis in adults. In clinical trials, Briumvi was found to significantly lower annualized relapse rates compared to Aubagio (teriflunomide).
Briumvi is an anti-CD20 monoclonal antibody approved for patients with relapsing MS that can be administered in a one-hour infusion following the starting dose. The first dose will last about four hours. The second dose will be given two weeks after the first dose with the infusion lasting about one hour. Subsequent infusions will be given as one infusion every 24 weeks and will last about one hour. Briumvi will be available for ordering early 2023.
Researchers showed Briumvi’s effectiveness in two randomized, double-blind, double-dummy, parallel group, active comparator-controlled clinical trials of identical design, in patients with RMS treated for 96 weeks. Patients were randomized to receive either Briumvi or teriflunomide, the active comparator.
The most common adverse reactions were infusion reactions, including fever, chills, headache, influenza-like illness, elevated heart rate, nausea, throat irritation, reddening of the skin (erythema) and an anaphylactic (allergic) reaction; infections including serious and fatal bacterial, fungal, and new or reactivated viral infections and reduction in immunoglobulins.
TG Therapeutics is a biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. To learn more, visit
briumvi.com
or
tgtherapeutics.com
.
MS Focus Lending Library
Books, DVDs, and CDs are available for loan, by mail across the United States.
Learn more